Dr. Ginige Swanthri Desilva, MD

Dr. Desilva practices at Allergy & Rheumatology Associates in Saint Petersburg, Florida.

Dr. Desilva's NPI, 1821183302, was assigned on October 3, 2006. Dr. Desilva graduated from The Flinders University of South Australia School of Medicine in 1995. Dr. Desilva holds Florida license ME91341.

Dr. Desilva's primary practice is Allergy & Rheumatology Associates, at 5100 Seminole Blvd, Saint Petersburg, FL 33708-3354. The practice phone is (727) 319-4535.

Dr. Desilva's primary practice is Allergy & Rheumatology Associates in Saint Petersburg, Florida. Dr. Desilva is also affiliated with BayCare St. Anthony's Hospital. The medical group on file is Allergy & Rheumatology Associates, LLC. Dmand AI also links Dr. Desilva to 3 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Desilva practices, 6 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Desilva's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Desilva is board certified in allergy & immunology by the American Board of Allergy and Immunology. Dmand AI has Dr. Desilva's licenses on file in 2 states: Florida and Texas.

Dmand AI lists acid reflux, arteritis, arthritis, asthma, bursitis, chronic diabetes, chronic hypertension and chronic kidney disease among the conditions Dr. Desilva treats.

CMS data shows 11,496 Medicare services from Dr. Desilva across 19 procedure codes in 2024, for 489 Medicare patients. Medicare paid $279,378 for them. Every service was in an office.

CMS counts 489 Medicare patients who saw Dr. Desilva in 2024. The largest group is 65 to 74, with 222 patients. 75% of them have arthritis, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 1.47, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Desilva's median patient age at 67, with 80% women.

In 2024, Dr. Desilva wrote 10,985 Medicare Part D claims for 1,258 patients. 89% of them were for generic drugs. CMS names the drug for 10,482 of them, across 100 drugs with 11 or more claims each, at $4,015,948 in total drug cost. In 2023, CMS named 9,867 claims across 96 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Desilva for performance year 2024, reported as part of a group. Dr. Desilva accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Desilva as offering telehealth.

CMS Open Payments shows 6 general payments to Dr. Desilva from 3 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 46% of the total. Novartis Pharmaceuticals Corporation paid the most, $227.

Dmand AI lists 1 award for Dr. Desilva, most recently CMS Stage 1 EHR in 2013.

Dr. Desilva graduated from The Flinders University of South Australia School of Medicine in 1995.

Dr. Desilva is in network with 17 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.